ライフサイエンスコーパス: dalteparin

1 y ill medical-surgical patients who received dalteparin.

2 dalteparin and 143 assigned to no antepartum dalteparin.

3 r (P < 0.001) but not superior (P = 0.22) to dalteparin.

4 onstrated significant increases following IV dalteparin.

5 bleeding was higher with edoxaban than with dalteparin.

6 nt analysis (dalteparin 28/143 [19.6%] vs no dalteparin 24/141 [17.0%]; risk difference +2.6% [95% CI

7 outcome in both intention-to-treat analysis (dalteparin 25/146 [17.1%; 95% CI 11.4-24.2%] vs no dalte

8 arin 25/146 [17.1%; 95% CI 11.4-24.2%] vs no dalteparin 27/143 [18.9%; 95% CI 12.8-26.3%]; risk diffe

9 -10.6% to 7.1%)) and on-treatment analysis (dalteparin 28/143 [19.6%] vs no dalteparin 24/141 [17.0%

10 hylaxis (33%), unfractionated heparin (29%), dalteparin (40%), or inferior vena cava filters (20%) we

11 ither a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, o

12 ratio to either antepartum prophylactic dose dalteparin (5000 international units once daily up to 20

13 en involving patients (n = 110) who received dalteparin 60 or 80 international U (IU)/kg alone or fol

14 Five min after administration of IV dalteparin 80 IU/kg the ACT increased from 125 s (122 s,

15 Dalteparin administration did not significantly improve

16 of 398 patients (1.3%) randomly assigned to dalteparin and 1 of 380 (0.3%) randomly assigned to aspi

17 p), leaving 146 women assigned to antepartum dalteparin and 143 assigned to no antepartum dalteparin.

18 ding occurred in 5 patients (1.3%) receiving dalteparin and 2 (0.5%) receiving aspirin.

19 enous thromboembolism were 2.4% and 3.3% for dalteparin and placebo, respectively, with bleeding rate

20 = 15) who were sequentially treated with IV dalteparin and then UFH.

21 zed 1:1 to verum (200 mg/ml 5-FU and 5 IU/ml dalteparin) and placebo (balanced salt solution) intravi

22 lines were treated with LMWH (Tinzaparin and Dalteparin), and DOAC (Apixaban and Rivaroxaban) and the

23 large clinical trials, including enoxaparin, dalteparin, and nadroparin, not all have shown better ef

24 dy weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (

25 once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weig

26 The ACT and aPTT are sensitive to IV dalteparin at clinically relevant doses.

27 ollowed by 5 mg twice daily) or subcutaneous dalteparin (at a dose of 200 IU per kilogram of body wei

28 y inhibitor (TFPI) concentration, and plasma dalteparin concentration.

29 ast 37 weeks' gestation) or to no antepartum dalteparin (control group).

30 Dalteparin did not reduce the incidence of the primary c

31 randomized trials comparing a DOAC with LMWH dalteparin differ in trial design and results.

32 Antepartum prophylactic dalteparin does not reduce the occurrence of venous thro

33 agulant effect of intravenously administered dalteparin during PCI.

34 ACT can be used to monitor intravenous (IV) dalteparin during percutaneous coronary intervention (PC

35 and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end poi

36 after THA in patients who initially received dalteparin for 10 days.

37 th aspirin was noninferior to and as safe as dalteparin for the prevention of VTE after THA in patien

38 ral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous

39 care payer perspective, the use of the LMWH dalteparin for VTE prophylaxis among critically ill medi

40 eparin group (28/143 [19.6%]) than in the no dalteparin group (13/141 [9.2%]; risk difference 10.4%,

41 wever, minor bleeding was more common in the dalteparin group (28/143 [19.6%]) than in the no daltepa

42 aban group and in 59 patients (11.3%) in the dalteparin group (difference in risk, -3.4 percentage po

43 xaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage poi

44 roup and in 46 of 579 patients (7.9%) in the dalteparin group (hazard ratio, 0.63; 95% confidence int

45 xaban group and in 23 patients (4.0%) in the dalteparin group (hazard ratio, 0.82; 95% CI, 0.40 to 1.

46 d with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence int

47 fety analysis there were 143 patients in the dalteparin group and 141 in the no dalteparin group.

48 ause of ineligibility (two in the antepartum dalteparin group and one in the control group), leaving

49 at a dose of 150 IU per kilogram once daily (dalteparin group).

50 ts in the dalteparin group and 141 in the no dalteparin group.

51 n treatment exhibited a higher DTH risk than dalteparin (hazard ratio [HR], 26.7; 95% CI, 3.4-211.0;

52 , which is significantly higher than that of dalteparin (HR, 26.7).

53 t costly unless the drug acquisition cost of dalteparin increased from $8 to $179 per dose and was co

54 Dalteparin induced a significant rise in the ACT with a

55 Prophylaxis with dalteparin is an effective and safe modality for the pre

56 atients were randomly assigned to 28 days of dalteparin (n = 400) or aspirin (n = 386).

57 ival was examined in a subgroup of patients (dalteparin, n = 55; and placebo, n = 47) who had a bette

58 sis suggests a potential modifying effect of dalteparin on tumor biology.

59 les spiked with increasing concentrations of dalteparin or UFH.

60 with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching plac

61 After an initial 10 days of dalteparin prophylaxis after elective THA, patients were

62 ntion group received vitamins and 5000 IU of dalteparin-sodium for up to 24 weeks' gestation.

63 eatment was not significantly different from dalteparin treatment (HR, 5.6; 95% CI, 0.3-96.1; P = .23

64 ignificantly improved for patients receiving dalteparin versus placebo (78% v 55% and 60% v 36%, resp

65 was designed to compare the dose response of dalteparin versus unfractionated heparin (UFH) on the ac

66 Dalteparin was administered to 120 adult renal transplan

67 s after randomization for patients receiving dalteparin were 46%, 27%, and 21%, respectively, compare

68 ral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recu

69 We postulated that antepartum dalteparin would reduce these complications in pregnant